Comprehensive overview of the pharmacogenetic diversity in Ashkenazi Jews. Zhou Y, Lauschke VM. J Med Genet. 2018 Sep;55(9):617-627. Posted on May 15, 2019 by Wendy van Hemmen Continue reading →
Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation. Cecchin E, De Mattia E, Ecca F, Toffoli G. Drug Resist Updat. 2018 Jul;39:18-40. Posted on May 15, 2019 by Wendy van Hemmen Continue reading →
From hype to reality: data science enabling personalized medicine. Fröhlich H, et al. BMC Med. 2018 Aug 27;16(1):150. Posted on May 15, 2019 by Wendy van Hemmen Continue reading →
Personalized laboratory medicine: a patient-centered future approach. Prodan Žitnik I, et al.; behalf of EFLM/ESPT working group of Personalised Laboratory Medicine on. Clin Chem Lab Med. 2018 Nov 27;56(12):1981-1991. Posted on May 15, 2019 by Wendy van Hemmen Continue reading →
Drinking Ethanol Has Few Acute Effects on CYP2C9, CYP2C19, NAT2, and P-Glycoprotein Activities but Somewhat Inhibits CYP1A2, CYP2D6, and Intestinal CYP3A: So What? Gazzaz M, et al. Clin Pharmacol Ther. 2018 Dec;104(6):1249-1259. Posted on May 15, 2019 by Wendy van Hemmen Continue reading →
Improving decision making on DPYD and UGT1A1*28 patients’ profiling with an innovative reimbursement strategy. Roncato R, Cecchin E, Toffoli G. Pharmacogenomics. 2018 Mar;19(4):301-304. Posted on May 15, 2019 by Wendy van Hemmen Continue reading →
How to Consider Rare Genetic Variants in Personalized Drug Therapy. Lauschke VM, Ingelman-Sundberg M. Clin Pharmacol Ther. 2018 May;103(5):745-748. Posted on May 15, 2019 by Wendy van Hemmen Continue reading →
CPIC Guideline for CYP2D6 and Tamoxifen Therapy. Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, Symmans WF, McLeod HL, Ratain MJ, Zembutsu H, Gaedigk A, van Schaik RH, Ingle JN, Caudle KE, Klein TE. Clin Pharmacol Ther. 2018 May;103(5):770-777. Posted on May 15, 2019 by Wendy van Hemmen Continue reading →
Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). Bergmeijer TO, et al.; ICPC Investigators. Am Heart J. 2018 Apr;198:152-159. Posted on May 15, 2019 by Wendy van Hemmen Continue reading →
Systemic regulation of bilirubin homeostasis: Potential benefits of hyperbilirubinemia. Fujiwara R, Haag M, Schaeffeler E, Nies AT, Zanger UM, Schwab M. Hepatology. 2018 Apr;67(4):1609-1619. Posted on May 15, 2019 by Wendy van Hemmen Continue reading →
